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Expression of beta human chorionic gonadotrophin by non-trophoblastic
non-endocrine 'normal' and malignant epithelial cells
R.K. Iles', P.E. Purkis2, P.C. Whitehead2, R.T.D. Oliver3, I. Leigh2 & T. Chard'
'Department of Reproductive Physiology, St Bartholomew's Hospital Medical College, London, UK; and the Imperial Cancer
Research Fund Departments of 2Experimental Dermatology and 3Medical Oncology, The London Hospital Medical College,
London, UK.
Summary Expression of hCG and its free subunits by non-trophoblastic tumours is well recognised.
Previously we reported hCG secretion by normal and malignant bladder epithelial cells in vitro. Here we
examined culture medium from 83 different cell lines derived mainly from common epithelial tumours.
Thirty-two of the cell lines were found to secrete hCG-like material into their culture media. Partial
immunochemical characterisation showed that of these only choriocarcinoma and fetal tissue cell lines
produced intact hCG and alpha subunit. The remaining 28 hCG-expressing epithelial cell lines, which are of
mucosal origin, only secreted free beta subunit. Expression of free beta hCG by non-trophoblastic non-
endocrine cells would appear to be especially characteristic of mucosal epithelia from the genitourinary and
oral/respiratory tracts. Furthermore, this phenomenon may be characteristic of epithelium with transitional
and/or squamous cell-like properties.
Detection of human chorionic gonadotrophin (hCG) in the
blood of non-pregnant subjects is most commonly associated
with germ cell tumours. In addition, hCG or either of its two
subunits can be found in the serum of some patients with
non-gonadal epithelial tumours. The highest incidence of the
latter is found with islet cell carcinomas (reviewed by Braun-
stein, 1983). We have previously reported the expression of
the free beta subunit of hCG as a common feature of neo-
plastic and 'normal' bladder epithelial cells in vitro (Iles et al.,
1987; Iles & Chard, 1989). Similarly, Cowley et al. (1985)
found that the secretion of free beta-hCG was a common
feature of a series of head and neck squamous carcinoma cell
lines. Here we report a survey of the in vitro hCG secretion
by 83 cell lines, derived in the main from common epithelial
tumours: lung, breast, ovarian, colorectal and bladder. The
secreted hCG was further subjected to detailed
immunochemical characterisation.
Materials and methods
Cell culture
A total of 83 established and finite cell lines were examined.
These included 10 testicular germ cell tumours; three
choriocarcinomas; 10 bladder cancers; eight 'normal'
urothelial lines; 12 oral and genital epidermoid and
squamous cell carcinoma (EC and SCC); four 'normal' oral
mucosa; eight normal and transformed skin keratinocytes;
five colorectal tumours; five lung carcinomas; seven breast
carcinomas; and five ovarian (epithelial) tumours. Six control
cell lines (three human and three murine) were also
examined.
Established cell lines cultured at the London Hospital were
from seed stocks donated by the originators, or from the
American Type Culture Collection (ATCC) and the Euro-
pean Collection of Animal Cell Cultures (ECACC). Medium
from other cell lines was donated by J. Masters (Institute of
Urology, London, UK); B. Hill (Imperial Cancer Research
Fund, London, UK); M. Turkish (Surgical Unit, The
London Hospital Medical College, London, UK); and P.
Lavender (Chemical Endocrinology Department, St Bar-
tholomew's Hospital, London, UK) (Table I). Finite cell lines
were used at passage three or more from primary culture. In
all cases cells were cultured for 96 h and the culture medium
harvested and stored at - 30°C until assayed as described
previously (Iles et al., 1987).
Table I The characteristics of cell lines used in this study
Tissue/tumour Cell lines
Testicular germ cell tumour Tera I (l,b); Tera II (l,b); 833K
(l,b); HL (l,b) 1618K (l,b); GCT-27
(l,b); GH (l,b); SuSa (l,b); WG007
(2,a); PJ077 (2,a)
Epithelial ovarian carcinoma KOD (2,a); SK-OV-3 (l,c); TRl170
(1,c); 1847 (1,c); TR175 (1,c)
Choriocarcinoma BeWo (l,a); JEG-3 (l,a); JAR (l,a)
Bladder carcinoma HT1376 (l,b); HCV-29 (l,b); RTI 12
( l,a); T24 (I ,a); RT4 (I ,a); TccSUP
(l,a); J82 (l,a); SCaBER (l,a); 5637
(l,a); TccDES (2,a)
Colo-rectal carcinoma AJB (2,d); HT29 (l,d); HRT-18 (1,d);
Colo205 (l,d); SW1463 (l ,d)
Breast carcinoma MCF-7 (l,a); H507 (l,a); T47D (l,a);
FR5 (2,a); MJ003 (2,a); BrCaPE
(2,a); ZR-75-1 (I ,a)
Oral and genital squamous/ A431 (l,a); CaSKI (I,a); Hela (l,a);
epidermal cell carcinomas KB (I,a); Hep2 (l,a); TR126 (l,a);
TR146 (l,a); HN-1-P (1,c); SCC-27
(l,a); SCC 12B (l,a); SCC-25 (l,a);
SCC-4 (l,a)
Small cell lung carcinoma Martin (I,e); Frei (I,e); Pocock (I,e);
Highgate (1,e); Ben (I,e)
'Normal' urothelium HU609 (l,b); HS0767 (l,b); NB/UI
(2,a); NB/AJ (2,a); NB/JOH (2,a);
NB/IB (2,a); NB/217 (2,a); NB/I 10
(2,a)
'Normal' oral mucosa OrMuA (2,a); OrMuB (2,a); OrMuC
(2,a); GUM.BL (2,a)
'Normal' epithelial cells FsKMM (2,a); Fsk.24/9 (2,a); PsEp
(2,a); FsK.D43 (2,a); BSep.D41 (2,a);
UV/K14 (l,a); HaCat (l,a); SV/K14
(l,a)
Controls: human fetus, FTF (2,a); human term placenta, 3ASubE
(l,a); human skin fibroblast, Malme3 (l,a); murine fibroblast (Swiss)
3T3 (2,a); murine epidermoid carcinoma SHINOGI (I,a); murine rectal
carcinoma, CMT (l,a). Cell line characteristic: (1) established; (2) finite.
Culture media source: (a) authors; (b) J. Masters, Institute of Urology;
(c) B. Hill, Imperial Cancer Research Fund; (d) M. Turkish, Surgical
Unit, The London Hospital; (e) P. Lavender, Chemical Endocrinology
Department, St Bartholomew's Hospital. Neoplastic finite cultures are
initial cell cultures from tumours where lines have not yet been fully
characterised. Established non-neoplastic cell lines had transformed
spontaneously (HU609; HS0767; Malme-3; HaCAT) by SV/40 virus
infection (SV/40; 3aSubE) and SV/40 virus followed by UV light
exposure (UV/K14).
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Immunological characterisation
All samples were initially assayed using a radioimmunoassay
(RIA) directed against the specific beta-subunit. The poly-
clonal anti-beta-hCG antibody (S424, ILS Ltd, London, UK)
employed in this assay recognises both free beta-subunit and
intact hormone and has been described by Norman et al.
(1985). Material reactive in this assay is therefore referred to
as 'beta'-hCG. Standards were obtained from the National
Institute of Biological Standards, Potters Bar, Hertfordshire,
UK (intact hCG, Third International Standard Preparation
75/537). Free beta-subunit is used as tracer (NIH preparation
CR123). The lowest standard is 15mIUml-' in this assay
but a detection limit of 25mIUml-' has been used. Both
intact and free beta-hCG give equal displacement (100%
cross-reaction); alpha subunit and LH show a 2% cross-
reaction. The common alpha-subunit was estimated by the
RIA of Hagen et al. (1976). This assay uses alpha-hCG (NIH
preparation CR123) as standard and tracer. The polyclonal
rabbit anti-alpha-hCG antibody was provided by Dr J.G.
Pierce (UCLA School of Medicine). All of the glycoprotein
hormone alpha-subunits give equal displacement. Intact hCG
and LH show an 8% cross-reaction and beta-hCG less than
1%. Intact hCG was detected using a highly specific
qualitative two-site immunoenzymometric assay (Tandem
Icon II hCG; Hybritech Inc., San Diego, CA, USA). This
employs an immobilised monoclonal antibody to the alpha-
subunit as the capture antibody and a peroxidase-linked
anti-beta-subunit antibody for detection. The detection limit
is 25 mIU ml1'. All assays were validated for use with tissue
culture medium (Iles & Chard, 1989).
Results
Immunoreactive hCG was detected in the culture medium of
choriocarcinoma (3/3), bladder cancers (7/10), oral and
genital SCC and EC (6/12), lung carcinomas (4/5), 'normal'
urothelium (6/8) and 'normal' oral mucosa (3/4). Low levels
of hCG were also detected in the culture media of one of
eight skin keratinocyte cell lines and a control culture of fetal
fibroblasts (Table II and Figure 1). No hCG was detected in
cell lines from testicular germ cell tumours, epithelial ovarian
carcinomas, colorectal carcinomas and breast carcinomas.
Partial characterisation of the immunoreactive hCG is shown
in Table II. Material produced by choriocarcinoma cell lines
and the fetal fibroblast line reacted in the beta hCG, free
alpha subunit and intact hCG assays. All other culture media
reacted only in the beta hCG assay.
Discussion
Ectopic production of bioactive hCG-like material by non-
gestational tumours in vivo was reported as early as 1946
(McFadzean, 1946). Since the introduction of much more
specific and sensitive immological assays directed towards the
beta-subunit of the hormone many more tumours, particular-
ly those of germ cells, have been recognised as hCG pro-
ducers (Braunstein et al., 1973; Javadpour et al., 1978a, b).
The highest incidence of ectopic expression of hCG by
epithelial carcinomas is found with islet cell carcinomas
(45%) followed by ovarian carcinoma (39%) (reviewed by
Braunstein, 1983). The specificity of detection of very low
levels of hCG in association with epithelial tumours has
frequently been questioned (Adejuwon et al., 1980; Braun-
stein, 1983). In many series the levels reported ranged
between 5 and 25 mIU ml-' serum. Most hCG immuno-
assays have detection limit of between 5 and 15 mIU ml-'.
The accuracy of detection and quantification at the lower end
of a standard curve is poor. For this reason Braunstein
(1983) suggested that true 'ectopic' hCG expression should be
when levels above 25 mIU ml-' are found in serum. Never-
theless, using highly sensitive assay systems immunoreactive
hCG has been detected in lysates of some normal tissues
Table II Characterisation of 'hCG' in culture medium as determined
by specific immunoassays
Beta-hCG Alpha subunit
Cell culture (mIU ml') (ng ml') Intact hCG
Choriocarcinomas
JAR
BeWo
JEG-3
Bladder carcinomas
SCaBER
J82
RT4
5637
TccSUP
RT1 12
TccDES
Oral and genital SCC
and EC
A431
TR126
SCC12B
TR146
HN-1-P
CaSkl
Lung carcinomas
(small cell)
Martin
Frei
Pocock
Highgate
'Normal' urothelium
HU609
NBI 10
NB/JOH
NB/217
NB/U1
NB/AJ
NB/U2
'Normal' oral mucosa
Gum.BL
OrMu A
OrMu B
Skin keratinocyte
HaCAT
Control (Human)
FTF
500
E 200
(D) 100o
a 50
25
4800 .
3200 <
2500*
//
2500
4800
3200
2400
56
34
220
34
220
3600
110
230
38
55
440
40
35
75
55
44
1150
42
105
45
60
130
70
42
145
115
32
34
* 3600
* 2400
/1
18
250
180
<0.25
<0.25
<0.25
<0.25
<0.25
<0.25
< 0.25
+
<0.25
< 0.25
<0.25
< 0.25
<0.25
< 0.25
< 0.25
< 0.25
<0.25
<0.25
<0.25
< 0.25
<0.25
<0.25
< 0.25
< 0.25
< 0.25
< 0.25
< 0.25
< 0.25
< 0.25
8 +
.1150
/1
* 0
*-
lpw O"waIFm*
1 2 3 4 5 6 7 8
Neoplastic
Cell lines
*.
0
00 00-
-"--- ---m---------
9 10 11 12 13
Normal Control
Figure 1 Incidence and levels of immunoreactive hCG secreted
into the culture media by cell lines of different tumour/tissue
origin. Cell lines: 1, testicular germ cell tumours; 2, ovarian
carcinoma; 3, choriocarcinomas; 4, bladder carcinoma; 5, colorec-
tal carcinomas; 6, breast carcinomas; 7, oral and genital epider-
moid and squamous cell carcinomas; 8, lung carcinomas; 9, 'nor-
mal' urothelium; 10, 'normal' oral mucosa; 11, skin keratinocytes;
12, human controls; 13, murine controls.
(Yoshimoto et al., 1979a) and also at extremely low levels
(0.4-7.9 mIU ml-') in the serum of post-menopausal subjects
(Odell & Griffin, 1987). Most in vitro studies of ectopic hCG
*
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expression by non-trophoblastic/germ cell tumours have also
used highly sensitive assays (i.e. Ruddon et al. (1979),
0.5mIUml-1; Rosen et al. (1980), 0.02mIUmlh'). In the
present study we have used a conservative cut-off point
suggested by Braunstein (1983) (25mIUml1') for detection
of hCG-like material.
Substantial qualitative variability in the hCG material pro-
duced eutopically and ectopically has been reported
(Yoshimoto et al., 1979b). There often is an imbalance of
hCG subunit expression in both gestational and germ cell
tumours (Gaspard et al., 1980; Norman et al., 1985). Fur-
thermore, excessive production of free beta subunit appears
to be a prognostic indicator, identifying patients with high
risk gestational trophoblastic disease (Khazaeli et al., 1989).
Independent subunit expression is especially characteristic of
epithelial tumours (Weintraub & Rosen, 1973; Rosen &
Weintraub, 1974). However, in vitro studies do not always
parallel in vivo findings: for example, testicular germ cell
tumours have a high incidence of hCG expression in vivo, but
do not express the hormone when grown in long-term tissue
culture (Andrews et al., 1980; Iles et al., 1987). Previous
studies of tumour cell lines in vitro have reflected this
unbalanced expression of hCG subunits by neoplastic
epithelia (Ruddon et al., 1979; Rosen et al., 1980). In a
previous study we have shown that the hCG-like material
secreted by 'normal' and neoplastic bladder epithelial cell
lines consisted almost entirely of free beta-subunit (Iles &
Chard, 1989). The partial characterisation described here
strongly suggests that the hCG-like material produced by
some squamous cell, small cell and epidermoid carcinomas
and by 'normal' oral mucosa is also largely free beta subunit.
This is in agreement with the findings of Cowley et al. (1985).
The hCG-like material isolated from serum and urine of
patients with bladder cancer has also been shown to consist
mainly of free beta subunit, though smaller molecular weight
forms have been noted in urine (Hattori et al., 1980; Norman
et al., 1985; Rodenburg et al., 1985).
The metabolic clearance of hCG from the circulation
results in the formation of a number of products including
free beta subunit, asialo free beta subunit and free beta core
(Wehmann & Nisula, 1980; Blithe et al., 1988). These are
collectively known as urinary gonadotrophin fragments
(UGF) and are readily detected in pregnancy urine and that
of patients with trophoblastic disease (Kato & Braunstein,
1988; Birken et al., 1988). The smaller molecular weight
urinary beta core fragment is the sole measurable hCG
related cancer marker in some patients with non-
trophoblastic disease (Papapetrou '& Nicopoulou, 1986).
Indeed, beta core fragment can be detected in the urine of
normal healthy men (Kardana et al., 1988). This has led to
the suggestion that beta core may not simply be a metabolite
but may actually be synthesised by the trophoblast and a
variety of neoplastic and normal tissues (Kardana et al.,
1988; Cole et al., 1988; Cole & Birken, 1988). The 'beta' hCG
RIA used in the current studies detects all these fragments
but exact cross-reactivity cannot be calculated due to non-
parallelism by these fragments. Further characterisation is
necessary to determine whether one or all of these are present
(Iles & Chard, unpublished data). Most beta-hCG positive
samples were parallel on dilution. Variation on dilution
encountered in some samples is possibly due to the differing
affinity of our assay for epitopes recognised in complex mix-
tures of intact hCG, free beta, asialo free beta and beta-core.
However, we have previously identified whole beta subunit as
the major constituent hCG in the culture medium of 'normal'
and neoplastic urothelium (Iles & Chard, 1989).
This study suggests that expression of the free beta subunit
of hCG (or related UGF) is characteristic of some neoplastic
and normal epithelial cells from mucosal tissues. The genetic
complexity of the beta-hCG-LH gene-pseudogene cluster
makes it difficult to assess whether the same gene(s) active in
the placenta are also those expressed by these tissues (Iles et
al., 1989). It is of interest to note that the epithelial tumour
groups which did not secrete hCG-like material (breast, col-
orectum and ovary) are generally adenocarcinomas, while the
secreting carcinomas (bladder, lung, etc.) have squamous
metaplastic histology. Indeed, a recent histochemical study
has shown that beta-hCG expression by bladder tumours
correlates with the presence of squamous cell metaplasia
(Martin et al., 1989). As stated in vitro results do not always
correspond to in vivo findings. A recent study has correlated
beta-hCG expression by colonic cancers with poor prognosis
(Yamaguchi et al., 1989). None of the five colorectal cancer
lines studied here were found to secrete hCG-like material.
Despite this, it is possible to speculate that ectopic beta-hCG
expression may be a phenomenon of transitional cell/squa-
mous cell metaplasia. The fact that primary cultures of nor-
mal urothelium and oral mucosa also produced this peptide,
further indicates that this is not solely due to neoplastic
events.
We are most grateful to Dr J. Masters and Dr B. Hill, and Mr M.
Turkish and Mr P. Lavender for supplying us with tissue culture
media from various cell lines.
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